TY - JOUR
T1 - Activation of the neutrophil NADPH oxidase is inhibited by SB 203580, a specific inhibitor of SAPK2/p38
AU - Lal, Aroon S.
AU - Clifton, Andrew D.
AU - Rouse, John
AU - Segal, Anthony W.
AU - Cohen, Philip
PY - 1999/6/7
Y1 - 1999/6/7
N2 - Activation of the neutrophil NADPH oxidase by either the bacterial peptide fMLP or phorbol myristate acetate (PMA) is partially suppressed by SB 203580, a specific inhibitor of the MAP kinase family member, SAPK2/p38. The concentration of SB 203580 that suppresses activation of NADPH oxidase is similar to that which inhibits SAPK2/p38 in vitro, and both fMLP and PMA induce an extremely rapid and potent activation of SAPK2/p38 in neutrophils. SB 203580 does not exert its effect by preventing the neutrophil priming reaction, by suppressing the phosphorylation of p47(phax), or by preventing the translocation of p47(phax)/67(phax) to the plasma membrane.
AB - Activation of the neutrophil NADPH oxidase by either the bacterial peptide fMLP or phorbol myristate acetate (PMA) is partially suppressed by SB 203580, a specific inhibitor of the MAP kinase family member, SAPK2/p38. The concentration of SB 203580 that suppresses activation of NADPH oxidase is similar to that which inhibits SAPK2/p38 in vitro, and both fMLP and PMA induce an extremely rapid and potent activation of SAPK2/p38 in neutrophils. SB 203580 does not exert its effect by preventing the neutrophil priming reaction, by suppressing the phosphorylation of p47(phax), or by preventing the translocation of p47(phax)/67(phax) to the plasma membrane.
UR - http://www.scopus.com/inward/record.url?scp=0033532509&partnerID=8YFLogxK
U2 - 10.1006/bbrc.1999.0759
DO - 10.1006/bbrc.1999.0759
M3 - Article
C2 - 10362531
AN - SCOPUS:0033532509
SN - 0006-291X
VL - 259
SP - 465
EP - 470
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 2
ER -